PRKAA1 and infection: Physiological activation of AMPK resulted in a significant reduction of hepatic schizont size (252.8 ± 34 μm2 versus 399.6 ± 29 μm2, p < 0.0001; Figures 4H and 4I) and pre-patent blood stage infection (66% reduction, p < 0.01; Figure 4J), similar to salicylate treatment.